Ipsen (XPAR:IPN) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:IPN Ipsen SA XPAR:IPN
96 GF Score
Price €161.40
GF Value €134.45
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:IPN
96GF Score
Ipsen SA XPAR:IPN
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (XPAR:IPN) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €161.40 is trading 20% above its estimated GF Value™ of €134.45. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for XPAR:IPN:

  • Short Ratio:
  • GF Value™: €134.45 vs. price of €161.40 (20% above fair value)
  • GF Score™: 96/100 with 7 warning signs

No single metric tells the full story. See the XPAR:IPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
96GF Score

Get the complete analysis for XPAR:IPN

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€161.40
Price
€134.45
GF Value